Spruce Biosciences to Participate in the Craig-Hallum Biotech Catalyst ConferenceBusiness Wire · Oct 15, 2026
Spruce Biosciences Announces Presentation of MPS IIIB Natural History Data at the 55th Child Neurology Society Annual MeetingBusiness Wire · Oct 8, 2026
Spruce Biosciences to Participate in the H.C. Wainwright 28th Annual Global Investment ConferenceBusiness Wire · Sep 8, 2026
Spruce Biosciences Announces Launch of MPS3BStudy.comGuruFocus · Aug 26, 2026
Spruce Biosciences Announces Launch of MPS3BStudy.comBusiness Wire · Aug 26, 2026
Spruce Biosciences Announces Positive Pre-BLA Meetings with FDA and Confirms BLA Submission for TA-ERT on Track for Q4 2026Business Wire · Aug 24, 2026Spruce Biosciences, Inc., founded in 2014 and situated in Daly City, California, operates as a biopharmaceutical enterprise. Its primary objective is to advance and bring to market innovative treatments, particularly for uncommon endocrine conditions. A central component of its therapeutic pipeline is tildacerfont, a non-steroidal drug candidate.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 12, 2026 | -$5.79 | -$6.68 | Miss |
| May 13, 2026 | -$7.32 | -$8.94 | Miss |
| Mar 9, 2026 | -$12.87 | -$9.58 | Beat |
| Nov 10, 2025 | -$15.56 | -$14.58 | Beat |
| Aug 15, 2025 | -$18.00 | -$3.50 | Beat |
| May 6, 2025 | -$18.80 | -$24.00 | Miss |